The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...
There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...
New restrictions and safety checks on online pharmacies that prescribing high risk drugs, such as the weight loss drugs semaglutide and tirzepatide, could have a “significant” impact on GPs’ workload, ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
23hon MSN
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback